

Clinical trials of anti hypertensive agent for hypertension in very elderly (80 and more)

TrialResults-center www.trialresultscenter.org

1 beta-blockers

Trial	Treatments	Patients	Trials design and methods
atenolol vs control			
Coope (subgroup) , 1986 n=3/4 follow-up: 38y	atenolol and bendrofluazide versus control	patients aged 60 to 79 years	double-blind

References

Coope (subgroup) , 1986:

Coope J, Warrender TS Randomised trial of treatment of hypertension in elderly patients in primary care. Br Med J (Clin Res Ed) 1986;293:1145-51 [3094811]

2 beta-blockers + diuretics

Trial	Treatments	Patients	Trials design and methods
beta-blockers + diuretics vs placebo			
CASTEL (subgroup) , 1994 n=47/50 follow-up: 68y	active antihypertensive therapy (thiazide or beta-blockers) versus control	-	open

References

CASTEL (subgroup) , 1994:

Casiglia E, Spolaore P, Mazza A, Ginocchio G, Colangeli G, Onesto C, Di Menza G, Pegoraro L, Ambrosio GB Effect of two different therapeutic approaches on total and cardiovascular mortality in a Cardiovascular Study in the Elderly (CASTEL). Jpn Heart J 1994;35:589-600 [7830324]

3 beta-blockers or diuretics

Trial	Treatments	Patients	Trials design and methods
beta-blockers or diuretics vs placebo			

continued...

Trial	Treatments	Patients	Trials design and methods
STOP (subgroup) , 1991 n=122/113 follow-up: 21 y	active antihypertensive therapy (three beta-blockers and one diuretic) versus placebo	hypertensive Swedish men and women aged 70-84 years	double-blind Sweden

References

STOP (subgroup) , 1991:

Dahlf B, Lindholm LH, Hansson L, Scherstn B, Ekblom T, Wester PO Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension) Lancet 1991;338:1281-5 [[1682683](#)]

4 calcium-channel blockers

Trial	Treatments	Patients	Trials design and methods
nidrendipine vs placebo			
Syst-Eur (subgroup) , 1997 n=231/210 follow-up: 29 y	nitrendipine 10-40 mg daily in first step versus placebo	patients aged 60 years or older	double blind

References

Syst-Eur (subgroup) , 1997:

Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhger WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-64 [[9297994](#)]

5 diuretics

Trial	Treatments	Patients	Trials design and methods
chlorthalidone vs placebo			
SHEP-P (subgroup) , 1989 n=70/15 follow-up: 28y	chlorthalidone versus placebo	elderly participants with untreated blood pressures of greater than 160/less than 90 mm Hg	double-blind
SHEP (subgroup) , 1991 n=331/319 follow-up: 42y	chlorthalidone, 12.5 mg/d for step 1 versus placebo	patients aged 60 years and above	double blind
hydrochlorothiazide vs placebo			
EWPHÉ (subgroup) , 1985 n=70/85 follow-up: 31y	hydrochlorothiazide + triamterene versus placebo	patients over the age of 60	double-blind

continued...

Trial	Treatments	Patients	Trials design and methods
indapamide vs placebo			
HYVET , 2008 [NCT00122811] n=1933/1912 follow-up: 1.8y (median)	indapamide sustained release 1.5 mg/d + perindopril 2-4mg/d to obtain SBP<150 and DBP<80 versus placebo	patients 80 years or older with persistent hypertension defined as a sustained systolic BP of 160 mm Hg or higher	Parallel groups Double blind Western and Eastern Europe, China, Australasia, and North Africa

References

SHEP-P (subgroup), 1989:

Perry HM Jr, Smith WM, McDonald RH, Black D, Cutler JA, Furberg CD, Greenlick MR, Kuller LH, Schnaper HW, Schoenberger JA Morbidity and mortality in the Systolic Hypertension in the Elderly Program (SHEP) pilot study. Stroke 1989;20:4-13 [2911834]

SHEP (subgroup), 1991:

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA 1991;265:3255-64 [2046107]

EWPHE (subgroup), 1985:

Amery A, Birkenhger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-54 [2861311]

HYVET, 2008:

Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008 Mar 31;: [18378519]

6 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.